ABSTRACTS
SOLAR Abstract Submission Guidelines
SOLAR: Steatosis, Obesity, and Liver Disease Advances in Clinical Research
Abstract Submission Overview
Researchers are invited to submit abstracts for presentation at SOLAR, a scientific meeting focused on advances in steatotic liver disease, obesity, and related metabolic liver disorders. Accepted abstracts will be presented as posters, with a limited number selected for oral presentations.
Presentation Formats
- Poster Presentations: All accepted abstracts will be presented as posters.
- Oral Presentations: Five (5) top-scoring abstracts will be selected for oral presentation based on scientific merit, novelty, and clinical relevance.
Abstract Categories
- Clinical Epidemiology – Steatotic Liver Disease, Obesity, Cholestasis, Viral, and Metabolic Liver Disease
- Diagnostic Procedures – Steatotic Liver Disease and Liver Fibrosis
- Therapeutic Trials – Steatotic Liver Disease, Cholestatic Liver Disease, Viral hepatitis, Obesity, and Liver Fibrosis (Humans)
- Clinical Trial Design
- Disease Management of Steatotic/Viral/Cholestatic Liver Disease and Metabolic Comorbidities
- Obesity and Metabolic Dysfunction in Liver Disease
- Pharmacoeconomic and Societal Aspects
- Real-World Evidence and Outcomes Research
- Experimental/Basic Science –Liver Disease and obesity (Non-human)
- Pathogenesis and Translational Science –Liver Disease and Liver Fibrosis (Humans)
- Pharmacology and Emerging Therapeutics
- Non-Invasive Testing and Biomarkers
- Imaging and Digital Health in Liver Disease
- Pediatric Steatotic Liver Disease and Obesity
- Clinical trials of anti-obesity medications
- Bariatric surgery clinical outcomes
- Endoscopic or device-based obesity therapies
- Weight loss effects on cardiometabolic risk factors
- Obesity and type 2 diabetes outcomes
- Obesity and liver disease (MASLD/MASH) outcomes
- Body composition and metabolic changes with treatment
- Real-world effectiveness and safety of obesity therapies
- Lifestyle and structured weight management interventions
- Obesity-related comorbidities and clinical outcomes
Eligibility Criteria – Acceptable Research
- Clinical trials (all phases)
- Observational and real-world studies
- Translational research
- Diagnostic and biomarker studies
- Health outcomes and pharmacoeconomic research
- Basic and preclinical science
Industry-Sponsored Research
- Industry-sponsored and investigator-initiated studies are permitted.
- Studies involving investigational therapies are allowed.
Encore Abstract Policy
- Encore abstracts must be clearly identified at submission.
- Eligible for poster presentation.
- Not eligible for awards or oral presentation unless they include substantial new data, at Course Director discretion.
Late-Breaking Abstract Policy
- Recently completed clinical trials
- Practice-changing data
- Major safety or efficacy findings
- High-impact translational results
Late-breaking abstracts may be selected for poster or oral presentation at Course Director discretion.
Abstract Format Requirements
Maximum 500 words (excluding title and authors).
Key Dates
- Abstract Submission Opens: March 6, 2026
- Abstract Submission Deadline: June 5, 2026
- Acceptance Notifications: June 12, 2026
Presenter Responsibilities
- At least one author must register for the meeting.
- Poster presenters must be present during assigned poster sessions.
- Oral presenters must adhere to assigned presentation times.
Connecting liver, obesity, and metabolic science to improve patient care.
This conference looks at the bigger picture—how liver disease, obesity, and metabolic dysfunction intertwine. It creates a space where clinicians, researchers, and industry experts can break silos, share insights, and shape the future of care together. By weaving cutting-edge science with real-world clinical strategies, it challenges participants to rethink how breakthroughs move from the lab to the patient.